|
Match
|
Document |
Document Title |
|
|
US20050181971 |
Treatment of type i diabetes mellitus
Use of a growth hormone antagonist to reduce the overnight insulin requirement of a patient suffering from Type I diabetes mellitus or from dawn phenomenon. |
|
|
US20110230404 |
Glycoproteins Produced in Plants and Methods of Their Use
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive... |
|
|
US20120129766 |
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods... |
|
|
US20130150293 |
METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN
The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product. |
|
|
US20110256130 |
METHODS OF TREATING INFLAMMATORY DISORDERS
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of... |
|
|
US20140107022 |
CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20140094406 |
CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20130331317 |
CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20130331316 |
CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20110263495 |
METHODS AND KITS FOR TREATING DISEASE BY ADMINISTERING INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-2
The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present... |
|
|
US20100322894 |
Combination Therapies for Treating Type 1 Diabetes
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes. |
|
|
US20140155316 |
FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20110070237 |
METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM
Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in... |
|
|
US20110002994 |
METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to... |
|
|
US20110190730 |
METHODS OF INDUCING PLURIPOTENCY INVOLVING OCT4 PROTEIN
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell... |
|
|
US20140057832 |
USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE
The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present... |
|
|
US20110286997 |
Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes
Compositions and methods for the detection and treatment of T1D are provided. |
|
|
US20110236370 |
Genetic Alterations on Chromosomes 21q, 6q and 15q and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes
Compositions and methods for the detection and treatment of T1D are provided. |
|
|
US20120046224 |
TREATMENT OF DIABETES AND METABOLIC SYNDROME
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating... |
|
|
US20110190729 |
METHODS OF INDUCING PLURIPOTENCY INVOLVING SOX2 PROTEIN
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell... |
|
|
US20140243260 |
CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE
The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion... |
|
|
US20070172453 |
Tolerogenic approach for type 1 diabetes
The present invention provides compositions and methods for the treatment and prevention of type I diabetes. |
|
|
US20120232004 |
Methods for Treating Autoimmune Disorders, and Reagents Related Thereto
The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple... |
|
|
US20110262386 |
METHODS OF TREATING INFLAMMATION
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding... |
|
|
US20140221277 |
Method For Elevating Prolactin In Mammals
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also... |
|
|
US20130012431 |
Method For Elevating Prolactin In Mammals
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also... |
|
|
US20130130975 |
Methods of Treating Glucose Metabolism Disorders
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. |
|
|
US20150023984 |
Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment
Compositions and methods for the detection and treatment of T1D are provided. |
|
|
US20110243922 |
Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment
Compositions and methods for the detection and treatment of T1D are provided. |
|
|
US20120258094 |
METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE CTLA4 MOLECULE
The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from... |
|
|
US20140093519 |
METHODS FOR PANCREATIC TISSUE REGENERATION
Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of... |
|
|
US20140037634 |
REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A... |
|
|
US20130231277 |
CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”)... |
|
|
US20140213512 |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,... |
|
|
US20120277147 |
PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS
A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) a... |
|
|
US20130035280 |
Method and means for identifying substances which inhibit IgE production
The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is... |
|
|
US20110104156 |
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the... |
|
|
US20150111821 |
MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE
The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such... |
|
|
US20060008829 |
Multimarker panel based on PIGF for diabetes type 1 and 2
The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention... |
|
|
US20150164986 |
METHOD OF TREATING TYPE I DIABETES USING APOLIPOPROTEIN AIV
Methods for treating type one diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type one diabetes mellitus are disclosed, including combination... |
|
|
US20140328794 |
ALBUMIN FUSION PROTEINS
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors... |
|
|
US20140086903 |
CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as... |
|
|
US20080175921 |
Colloidal formulation of long-acting insulin and its preparation
The invention relates to injectable long-acting insulin formulations for the treatment of type I and II diabetes in humans and animals. The main objective of the invention is to provide a... |
|
|
US20140286906 |
USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES
The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or... |
|
|
US20120214729 |
COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION
The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits... |
|
|
US20140057838 |
OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM
Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and... |
|
|
US20150010508 |
Methods And Compositions Relating To Islet Cell Neogenesis
The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating... |
|
|
US20150099697 |
METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP)
Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the... |
|
|
US20110046055 |
THERAPEUTIC AGENT FOR DIABETES
Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to... |
|
|
US20060239934 |
SUPERIOR CONTROL OF BLOOD GLUCOSE IN DIABETES TREATMENT
Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose... |